ANZCTR - Registration

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02422797

Registration number

NCT02422797

Ethics application status

Date submitted

9/04/2015

Date registered

21/04/2015

Date last updated

3/09/2024

Titles & IDs

Public title

Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)

Scientific title

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed

Secondary ID [1]

2014-005148-16

Secondary ID [2]

201637

Universal Trial Number (UTN)

Trial acronym

Linked study record

Health condition

Health condition(s) or problem(s) studied:

HIV Infections

Condition category

Condition code

Infection

Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

Treatment: Drugs - DTG 50 mg
Treatment: Drugs - RPV 25 mg
Treatment: Drugs - CAR

Active comparator: Current antiretroviral regimen (CAR) - Participants continued to receive their current antiretroviral regimen (two nucleoside reverse transcriptase inhibitor \[NRTIs\] + a third agent). A third agent included either an: integrase strand transfer inhibitor (INSTI), a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI). CAR was administered according to the approved labeling in an open-label fashion up to Week 52 during early switch phase. At Week 52, participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) \<50 copies per milliliter (c/mL), switched to DTG 50 mg + RPV 25 mg once daily and were followed-up through the Late Switch Phase, at Week 148 and through the Continuation Phase, after Week 148.

Experimental: DTG + RPV - Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.

Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148).

Treatment: Drugs: DTG 50 mg
Participants received one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet contained 52.62 mg dolutegravir sodium salt, which was equivalent to 50 mg dolutegravir free acid.

Treatment: Drugs: RPV 25 mg
Participants received DTG 50 milligrams (mg) + RPV 25 mg together once daily at approximately the same time, with a meal, in an open-label fashion up to Week 52 during early switch phase. Participants continued to receive DTG 50 mg + RPV 25 mg up to Week 148 during the Late Switch Phase.

Participants who successfully completed 148 weeks of treatment were given the opportunity to continue to receive DTG + RPV once daily in the Continuation Phase (after Week 148), one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet contained 27.5 mg of rilpivirine hydrochloride, which was equivalent to 25 mg of RPV.

Treatment: Drugs: CAR
CAR included the following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.

Intervention code [1]

Treatment: Drugs

Comparator / control treatment

Control group

Outcomes

Primary outcome [1]

Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm

Timepoint [1]

Week 48

Secondary outcome [1]

Changes From Baseline in Cluster Designation (CD)4+ Lymphocyte Count at Weeks 24 and 48

Timepoint [1]

At Weeks 24 and 48

Secondary outcome [2]

Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 24 Using Snapshot Algorithm

Timepoint [2]

Week 24

Secondary outcome [3]

Number of Participants With Common Non-serious Adverse Event (AE), Any Serious AE (SAE), AE of Maximum Toxicity Grade 1, 2, 3 or 4 and AE Leading to Discontinuation (AELD)

Timepoint [3]

Up to Week 410 or study discontinuation

Secondary outcome [4]

Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks

Timepoint [4]

Up to 48 weeks

Secondary outcome [5]

Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks

Timepoint [5]

Up to 48 weeks

Secondary outcome [6]

Mean Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 48

Timepoint [6]

At Week 48

Secondary outcome [7]

Mean Change From Baseline in Cystatin C at Week 48

Timepoint [7]

At Week 48

Secondary outcome [8]

Mean Change From Baseline in D-Dimer at Week 48

Timepoint [8]

At Week 48

Secondary outcome [9]

Mean Change From Baseline in Fatty Acid Binding Protein 2 (FABP) and Soluble CD14 at Week 48

Timepoint [9]

At Week 48

Secondary outcome [10]

Mean Change From Baseline in Soluble CD163 and Oxidized Low Density Lipoprotein (LDL) at Week 48

Timepoint [10]

At Week 48

Secondary outcome [11]

Mean Change From Baseline in Retinol Binding Protein (RBP), Serum Creatinine and Glucose at Week 48

Timepoint [11]

At Week 48

Secondary outcome [12]

Mean Change From Baseline in Urine Phosphate at Week 48

Timepoint [12]

At Week 48

Secondary outcome [13]

Mean Change From Baseline in Beta-2-microglobulin (B2M) (Blood and Urine), Urine RBP and 25 Hydroxy-vitamin D (Blood) at Week 48

Timepoint [13]

At Week 48

Secondary outcome [14]

Mean Change From Baseline in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio at Week 48

Timepoint [14]

At Week 48

Secondary outcome [15]

Mean Change From Baseline in Bone-specific Alkaline Phosphatase, Procollagen 1 N-terminal Propeptide, Osteocalcin, Type 1 Collagen C-telopeptides and Soluble Vascular Cell Adhesion Molecule (sVCAM) at Week 48

Timepoint [15]

At Week 48

Secondary outcome [16]

Mean Change From Baseline in Interleukin 6 (IL-6) at Week 48

Timepoint [16]

At Week 48

Secondary outcome [17]

Mean Change From Baseline in Insulin Resistance Based on Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at Week 48

Timepoint [17]

At Week 48

Secondary outcome [18]

Mean Change From Baseline in Fasting Lipids at Weeks 24 and 48

Timepoint [18]

At Weeks 24 and 48

Secondary outcome [19]

Number of Participants With Genotypic Resistance-Early Switch Phase

Timepoint [19]

Up to Week 48

Secondary outcome [20]

Number of Participants With Genotypic Resistance-DTG+RPV Arm Through Early and Late Switch Phase

Timepoint [20]

Up to Week 148

Secondary outcome [21]

Number of Participants With Genotypic Resistance-CAR Arm Through Late Switch Phase

Timepoint [21]

Post-Late switch (LS) Baseline (Week 52) up to Week 148

Secondary outcome [22]

Number of Participants With Phenotypic Resistance-Early Switch Phase

Timepoint [22]

Up to Week 52

Secondary outcome [23]

Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Early and Late Switch Phase

Timepoint [23]

Up to Week 148

Secondary outcome [24]

Number of Participants With Phenotypic Resistance-CAR Group Through Late Switch Phase

Timepoint [24]

Post-LS Baseline (Week 52) up to Week 148

Secondary outcome [25]

Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - DTG+RPV Group Through Early and Late Switch Phase

Timepoint [25]

Pre-dose at Week 4, 24, 48, 56, 76 and 100

Secondary outcome [26]

Pre-dose Concentrations of DTG and RPV in Participants Switching to DTG + RPV - CAR Group Through Late Switch Phase

Timepoint [26]

Pre-dose at Weeks 56, 76 and 100

Secondary outcome [27]

Pre-dose Concentrations of DTG and RPV in the First 20 Participants Who Switch From Efavirenz (EFV) or Nevirapine (NVP) to DTG + RPV

Timepoint [27]

Pre-dose at Weeks 2, 4 and 8

Secondary outcome [28]

Percentage of Participants With Plasma HIV 1 RNA <50 c/mL at Week 48 Using Snapshot Algorithm by Baseline Third Agent Treatment Class

Timepoint [28]

At Week 48

Secondary outcome [29]

Changes From Baseline in CD4+ Lymphocyte Count at Week 48 by Baseline Third Agent Treatment Class

Timepoint [29]

At Week 48

Secondary outcome [30]

Number of Participants With Any AE, AELD or AE With Grade 1, 2, 3 or 4 Toxicity Over 48 Weeks by Baseline Third Agent Treatment Class

Timepoint [30]

Up to 48 weeks

Secondary outcome [31]

Number of Participants With Maximum Post-baseline Emergent Chemistry Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class

Timepoint [31]

Up to 48 weeks

Secondary outcome [32]

Number of Participants With Maximum Post-baseline Emergent Hematology Toxicities Over 48 Weeks by Baseline Third Agent Treatment Class

Timepoint [32]

Up to 48 weeks

Secondary outcome [33]

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class

Timepoint [33]

Week 48

Secondary outcome [34]

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class

Timepoint [34]

Week 48

Secondary outcome [35]

Change From Baseline in Fasting Lipids at Weeks 24 and 48 by Baseline Third Agent Treatment Class

Timepoint [35]

At Weeks 24 and 48

Secondary outcome [36]

Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 4, 24 and 48-Early Switch Phase

Timepoint [36]

At Weeks 4, 24 and 48

Secondary outcome [37]

Change From Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

Timepoint [37]

At Weeks 56, 76, 100 and 148

Secondary outcome [38]

Change From LS Baseline in Pre-specified Treatment Symptoms Using the Symptom Distress Module at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase

Timepoint [38]

At Weeks 56, 76, 100 and 148

Secondary outcome [39]

Change From Baseline Treatment Satisfaction Using the HIV Treatment Satisfaction Questionnaire (HIV TSQ) at Weeks 4, 24 and 48-Early Switch Phase

Timepoint [39]

At Weeks 4, 24 and 48

Secondary outcome [40]

Change From Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-DTG+RPV Group Through Early and Late Switch Phase

Timepoint [40]

At Weeks 56, 76, 100 and 148

Secondary outcome [41]

Change From LS Baseline Treatment Satisfaction Using the HIV TSQ at Weeks 56, 76, 100 and 148-CAR Group Through Late Switch Phase

Timepoint [41]

At Weeks 56, 76, 100 and 148

Secondary outcome [42]

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase

Timepoint [42]

Up to Week 410

Secondary outcome [43]

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class-DTG+RPV Group Through Continuation Phase

Timepoint [43]

Up to Week 410

Secondary outcome [44]

Number of Participants With Observed Genotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class CAR Group Through Continuation Phase

Timepoint [44]

Week 52 to Week 410

Secondary outcome [45]

Number of Participants With Observed Phenotypic Resistance for Participants Meeting Virologic Withdrawal Criteria by Baseline Third Agent Treatment Class- CAR Group Through Continuation Phase

Timepoint [45]

Week 52 to Week 410

Secondary outcome [46]

Number of Participants With Genotypic Resistance-DTG+RPV Group Through Continuation Phase

Timepoint [46]

Up to Week 410

Secondary outcome [47]

Number of Participants With Phenotypic Resistance-DTG+RPV Group Through Continuation Phase

Timepoint [47]

Up to Week 410

Secondary outcome [48]

Number of Participants With Genotypic Resistance-CAR Group Through Continuation Phase

Timepoint [48]

Week 52 to Week 410

Secondary outcome [49]

Number of Participants With Phenotypic Resistance- CAR Group Through Continuation Phase

Timepoint [49]

Week 52 to Week 410

Eligibility

Key inclusion criteria

* Participants must have been able to understand and comply with protocol requirements, instructions, and restrictions.
* Participants must have been likely to complete the study as planned.
* Participants must have been considered appropriate candidates for participation in an investigative clinical trial with oral medication (e.g., no active substance abuse, acute major organ disease, or planned long-term work assignments out of the country, etc.).
* HIV-1 infected men or women of greater than or equal to (>=)18 years of age.
* Must have been on uninterrupted current regimen (either the initial or second combination antiretroviral therapy [cART] regimen) for at least 6 months prior to screening; Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability and/or safety concerns or access to medications, or convenience/simplification. Acceptable stable cART regimens prior to screening include 2 NRTIs plus INI (either the initial or second cART regimen), or an NNRTI (either the initial or second cART regimen), or a Boosted PI (or atazanavir unboosted) (either the initial or second PI-based cART regimen).
* Documented evidence of at least two plasma HIV-1 RNA measurements <50 c/mL in the 12 months prior to Screening: one within the 6 to 12 month window, and one within 6 months prior to Screening;
* Plasma HIV-1 RNA <50 c/mL at Screening;
* A female may have been eligible to enter and participate in the study if she was of : Non-child-bearing potential either defined as post-menopausal (12 months of spontaneous amenorrhea and >=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or, Child-bearing potential with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the following methods of contraception to avoid pregnancy: Complete abstinence from intercourse from 2 weeks prior to administration of study drug, throughout the study, and for at least 2 weeks after discontinuation of all study medications and completion of the Follow-up visit; Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year (not all IUDs meet this criterion); Male partner sterilization with documentation of azoospermia prior to the female participant's entry into the study and this male is the sole partner for that participant; The documentation on male sterility could come from the site personnel's review of participant's medical records, medical examination, and/or semen analysis, or medical history interview provided by her or her partner; Approved hormonal contraception for participants randomly assigned to DTG + RPV arm (and for participants randomly assigned to CAR following switch to DTG + RPV at Week 52) or approved hormonal contraception plus a barrier method for participants assigned to CAR through Week 52; Approved hormonal contraception included: Combined estrogen and progestogen oral contraceptive, Contraceptive subdermal implant, Injectable progestogen, Contraceptive vaginal ring, Percutaneous contraceptive patches. Any other method with published data showing that the expected failure rate is <1% per year. Any contraception method must have been used consistently, in accordance with the approved product label during treatment with study drug and for at least 2 weeks after discontinuation of study drug and completion of the Follow-Up Visit. The investigator was responsible for ensuring that participants understand how to properly use these methods of contraception. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal were not acceptable methods of contraception.
* Participants who were willing and able to understand requirements of study participation and provided signed and dated written informed consent prior to screening.
* For participants enrolled in France: participants were eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Minimum age

18 Years

Maximum age

No limit

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

Exclusionary Criteria prior to screening or Day 1:

* Within 6 months prior to Screening and after confirmed suppression to <50 c/mL on current ART regimen, any plasma HIV-1 RNA measurement >=50 c/mL.
* Within the 6 to 12 month window prior to screening and after confirmed suppression to <50 c/mL, any plasma HIV-1 RNA measurement >200 c/mL.
* Within the 6 to 12 month window prior to screening and after confirmed suppression to <50 c/mL, 2 or more plasma HIV-1 RNA measurements >=50 c/mL.
* Any drug holiday during the window between initiating first HIV ART and 6 months prior to screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and/or safety concerns.
* Any switch to a second line regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV 1 RNA measurement >=400 c/mL after initial suppression to <50 c/mL while on first line HIV therapy regimen).

Exclusionary medical conditions:

* Women who were pregnant, breastfeeding or planned to become pregnant or breastfeed during the study.
* Any evidence of an active Centers for Disease Control and Prevention Category C disease. Exceptions included cutaneous Kaposi's sarcoma not requiring systemic therapy and historic CD4+ lymphocyte counts of <200 cells per cubic millimeter (cells/mm^3).
* Participants with severe hepatic impairment (Class C) as determined by Child-Pugh Classification.
* Unstable liver disease (as defined by the presence of any of the following: ascites, encephalopathy, coagulopathy, hypoalbuminemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* Evidence of Hepatitis B virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), and Hepatitis B surface antibody (HBsAb) as follows: Participants positive for HBsAg were excluded; Participants positive for anti-HBc (negative HBsAg status) and negative for HBsAb were excluded.
* Participants with an anticipated need for any Hepatitis C virus (HCV) therapy during the Early Switch Phase and for interferon-based therapy for HCV throughout the entire study period.
* History or presence of allergy to the study drugs or their components or drugs of their class;
* Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the participant prior to randomization;
* Participants who in the investigator's judgment posed a significant suicidality risk. Participant's history of suicidal behavior and/or suicidal ideation should have been considered when evaluating for suicide risk;
* Any pre-existing physical or mental condition which, in the opinion of the Investigator, could have interfered with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which could have compromised the safety of the participants;
* Any condition which, in the opinion of the Investigator, could have interfered with the absorption, distribution, metabolism or excretion of the study drugs or render the participant unable to take oral medication;

Exclusionary Treatments prior to Screening or Day 1:

* Use of medications which were associated with Torsades de Pointes.
* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
* Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter immune responses.
* Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study.
* Participants who were participating or anticipated to be selected to participate in any other interventional study, with the exception of the DEXA sub-study 202094, after randomization
* A history of use of any regimen consisting of only single NNRTI therapy (even if only for peri-partum treatment), or only single or dual NRTI therapy prior to starting cART.
* Current or prior history of etravirine (ETR) use.
* Current use of tipranavir/ritonavir or fosamprenavir/ritonavir.
* Participants receiving any prohibited medication and who were unwilling or unable to switch to an alternate medication.

Exclusionary Laboratory Values or Clinical Assessments at Screening:

* Evidence of viral resistance based on the presence of any resistance associated major PI, INI, NRTI, or NNRTI mutation and integrase (IN) resistance associated substitution R263K in any available prior resistance genotype assay results.
* Any verified Grade 4 laboratory abnormality, with the exception of Grade 4 lipid abnormalities. A single repeat test was allowed during the Screening period to verify a result.
* Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
* Alanine aminotransferase (ALT) >=5 × upper limit of normal (ULN), or ALT >=3 × ULN and bilirubin >=1.5 × ULN (with greater than [>] 35% direct bilirubin).
* Corrected QT interval (QTc [Bazett]) >450 milliseconds or QTc (Bazett) >480 milliseconds for participants with bundle branch block. The QTc was the QT interval corrected for heart rate according to Bazett's formula (QTcB).

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

Masking / blinding

Open (masking not used)

Who is / are masked / blinded?

Intervention assignment

Parallel

Other design features

Phase

Phase 3

Type of endpoint/s

Statistical methods / analysis

Recruitment

Recruitment status

Completed

Data analysis

Reason for early stopping/withdrawal

Other reasons

Date of first participant enrolment

Anticipated

Actual

21/04/2015

Date of last participant enrolment

Anticipated

Actual

Date of last data collection

Anticipated

Actual

25/05/2023

Sample size

Target

Accrual to date

Final

518

Recruitment in Australia

Recruitment state(s)

Recruitment hospital [1]

GSK Investigational Site - Darlinghurst

Recruitment hospital [2]

GSK Investigational Site - Sydney

Recruitment postcode(s) [1]

2010 - Darlinghurst

Recruitment postcode(s) [2]

2010 - Sydney

Recruitment outside Australia

Country [1]

United States of America

State/province [1]

California

Country [2]

United States of America

State/province [2]

District of Columbia

Country [3]

United States of America

State/province [3]

Florida

Country [4]

United States of America

State/province [4]

Georgia

Country [5]

United States of America

State/province [5]

Michigan

Country [6]

United States of America

State/province [6]

Nebraska

Country [7]

United States of America

State/province [7]

North Carolina

Country [8]

United States of America

State/province [8]

Texas

Country [9]

United States of America

State/province [9]

Washington

Country [10]

Argentina

State/province [10]

Buenos Aires

Country [11]

Argentina

State/province [11]

Rosario

Country [12]

Canada

State/province [12]

Montreal

Country [13]

Canada

State/province [13]

Regina

Country [14]

Canada

State/province [14]

Toronto

Country [15]

Canada

State/province [15]

Vancouver

Country [16]

France

State/province [16]

Bordeaux

Country [17]

France

State/province [17]

Lyon

Country [18]

France

State/province [18]

Marseille

Country [19]

France

State/province [19]

Paris Cedex 20

Country [20]

France

State/province [20]

Saint-Denis Cedex

Country [21]

France

State/province [21]

Tourcoing cedex

Country [22]

Germany

State/province [22]

Berlin

Country [23]

Germany

State/province [23]

Bonn

Country [24]

Germany

State/province [24]

Hannover

Country [25]

Germany

State/province [25]

Koeln

Country [26]

Italy

State/province [26]

Bergamo

Country [27]

Italy

State/province [27]

Milano

Country [28]

Russian Federation

State/province [28]

Barnaul

Country [29]

Russian Federation

State/province [29]

Krasnodar

Country [30]

Russian Federation

State/province [30]

Saratov

Country [31]

Russian Federation

State/province [31]

St Petersburg

Country [32]

Spain

State/province [32]

A CoruNa

Country [33]

Spain

State/province [33]

Alicante

Country [34]

Spain

State/province [34]

Badalona

Country [35]

Spain

State/province [35]

Barcelona

Country [36]

Spain

State/province [36]

Cartagena

Country [37]

Spain

State/province [37]

Madrid

Country [38]

Spain

State/province [38]

Murcia

Country [39]

Spain

State/province [39]

Móstoles

Country [40]

Spain

State/province [40]

Oviedo

Country [41]

Spain

State/province [41]

Santa Cruz La Laguna

Country [42]

Spain

State/province [42]

Santiago de Compostela

Country [43]

Spain

State/province [43]

Valencia

Country [44]

Taiwan

State/province [44]

Kaohsiung City

Country [45]

Taiwan

State/province [45]

Kaohsiung

Country [46]

Taiwan

State/province [46]

New Taipei

Country [47]

Taiwan

State/province [47]

Taichung

Country [48]

United Kingdom

State/province [48]

London

Funding & Sponsors

Primary sponsor type

Commercial sector/industry

Name

ViiV Healthcare

Address

Country

Other collaborator category [1]

Commercial sector/industry

Name [1]

Janssen Pharmaceuticals

Address [1]

Country [1]

Other collaborator category [2]

Commercial sector/industry

Name [2]

GlaxoSmithKline

Address [2]

Country [2]

Ethics approval

Ethics application status

Summary

Brief summary

The aim of this study was to determine if virologically suppressed, human immunodeficiency virus type 1 (HIV-1) infected adults on an antiretroviral regimen (including 2 nucleoside reverse transcriptase inhibitors \[NRTIs\] plus a third agent) remain suppressed upon switching to a two-drug regimen with dolutegravir (DTG) + rilpivirine (RPV). The study primarily assessed the non-inferiority antiviral activity of switching to DTG + RPV once daily compared to the continuation of current antiretroviral regimen (CAR) up to Week 48 with a switch visit for eligible subjects in the CAR group to initiate DTG + RPV therapy at Week 52. CAR included 2 NRTIs plus 1 HIV-1 integrase inhibitor (INI), or 1 non-nucleoside reverse transcriptase inhibitor (NNRTI), or 1 protease inhibitor (PI). The study included a 148-week open-label treatment phase, comprising of an Early Switch Phase (Day 1 to Week 52) and a Late Switch Phase (Week 52 to Week 148). The participants fulfilling the study eligibility criteria participated in the Early Switch Phase where they either switched from their CAR to DTG + RPV, or continued taking their CAR, until Week 52. At the end of Early Switch Phase, eligible participants proceeded to the Late Switch Phase where all participants in both DTG + RPV and CAR treatment groups received DTG + RPV therapy until Week 148. After Week 148, subjects could have been eligible to continue to receive DTG +RPV in the Continuation Phase.

Trial website

https://clinicaltrials.gov/study/NCT02422797

Trial related presentations / publications

Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir plus rilpivirine for the maintenance of virologic suppression in HIV-1-infected adults: the phase III, randomized, open-label, active-controlled, noninferiority SWORD-1 and SWORD-2 studies. Lancet [epublished ahead of print] 6 January 2018.
Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K, Kahl LP, Blair EA, Adkison K, Underwood M, Matthews JE, Wynne B, Vandermeulen K, Gartland M, Smith K. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019 Sep;6(9):e576-e587. doi: 10.1016/S2352-3018(19)30149-3. Epub 2019 Jul 12.
Llibre JM, Hung CC, Brinson C, Castelli F, Girard PM, Kahl LP, Blair EA, Angelis K, Wynne B, Vandermeulen K, Underwood M, Smith K, Gartland M, Aboud M. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018 Mar 3;391(10123):839-849. doi: 10.1016/S0140-6736(17)33095-7. Epub 2018 Jan 6. Erratum In: Lancet. 2018 Jun 16;391(10138):2416. doi: 10.1016/S0140-6736(18)30200-9.
McComsey GA, Lupo S, Parks D, Poggio MC, De Wet J, Kahl LP, Angelis K, Wynne B, Vandermeulen K, Gartland M, Cupo M, Aboud M; 202094 Sub-Study Investigators. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health. AIDS. 2018 Feb 20;32(4):477-485. doi: 10.1097/QAD.0000000000001725.

Public notes

Contacts

Principal investigator

Name

GSK Clinical Trials

Address

ViiV Healthcare

Country

Phone

Fax

Contact person for public queries

Name

Address

Country

Phone

Fax

Contact person for scientific queries

Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02422797

Trial Review

Did you know?

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02422797